Bellerophon Revenue and Competitors
Estimated Revenue & Valuation
- Bellerophon's estimated annual revenue is currently $2.6M per year.
- Bellerophon's estimated revenue per employee is $155,000
Employee Data
- Bellerophon has 17 Employees.
- Bellerophon grew their employee count by -51% last year.
Bellerophon's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Officer, VP Engineering and Manufacturing | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Clinical Operations & Administration | Reveal Email/Phone |
4 | VP Business Operations | Reveal Email/Phone |
5 | Associate Director, Contracts | Reveal Email/Phone |
6 | Finance & HR Manager | Reveal Email/Phone |
7 | Sr. Program Manager | Reveal Email/Phone |
8 | Clinical Supply Adminstrator | Reveal Email/Phone |
Bellerophon Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $19.1M | 84 | 8% | N/A | N/A |
What Is Bellerophon?
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
keywords:N/A
N/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
-51%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Bellerophon News
Bellerophon Therapeutics (NASDAQ: BLPH) has recently received a number of price target changes and ratings updates: 4/19/2022 Bellerophon...
Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Bellerophon Therapeutics...
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company),...
Other Companies in Warren
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 17 | -35% | N/A |
#2 | $1.5M | 17 | 6% | N/A |
#3 | $2.6M | 17 | -23% | N/A |
#4 | $3.4M | 17 | -53% | N/A |
#5 | $1.5M | 17 | 13% | N/A |